CaaMTech

What CaaMTech does

CaaMTech, Inc. is a privately held pharmaceutical drug discovery company headquartered in Issaquah, Washington, founded in 2016 by Dr. Andrew Chadeayne. The company engineers next-generation psychedelic-inspired small-molecule therapeutics for mental health conditions including Major Depressive Disorder, PTSD, addiction, and other neuropsychiatric disorders. Its core asset is a proprietary library of hundreds of novel serotonergic compounds synthesized and crystallographically characterized since 2016, protected by a portfolio of more than 200 pending patent applications and issued patents. The lead clinical program, CT-4201, is a novel psilocin prodrug with improved pharmacokinetics relative to psilocybin being developed for Major Depressive Disorder; the FDA validated the program's functional unblinding strategy in November 2024.

CaaMTech's technology platform combines synthetic tryptamine chemistry with X-ray crystallography — the gold standard for chemical characterization — to generate structure-activity relationship data for lead optimization. The company maintains an active international research network, including collaborations with UMass Dartmouth's Manke Lab (which has synthesized 70+ novel tryptamines and structurally characterized 40+), a CRADA with NIDA's Designer Drug Research Unit, and partnerships with the Leibniz Institute (HKI Jena), Max Planck Institute for Chemical Ecology, the Medical College of Wisconsin, and the Alexander Shulgin Research Institute. In April 2025, CaaMTech spun out Transneural Therapeutics, Inc. to develop non-hallucinogenic neuroplastogens, with TN-001 (a dual 5-HT2A partial agonist/5-HT2B antagonist) as its lead candidate.

The company operates on a licensing/royalty business model: it is pre-revenue and intends to monetize its pipeline by advancing drug candidates through clinical trials and out-licensing or partnering with larger pharmaceutical companies for commercialization. CaaMTech is funded by a $22 million Series A led by Noetic Fund in September 2021 and does not sell products directly to consumers. Distribution of its compounds and intellectual property occurs through research collaborations, CRADA arrangements, and licensing to enterprise pharmaceutical partners. The go-to-market motion is enterprise-focused, centered on advancing CT-4201 through FDA-regulated clinical development and securing pharma partnerships at commercial readiness milestones.

Name

CaaMTech

Legal name

CaaMTech, Inc.

Website

https://caam.tech

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

CaaMTech is a private pharmaceutical drug discovery company engineering next-generation psychedelic-inspired serotonergic therapeutics for mental health conditions, anchored by a proprietary library of hundreds of crystallographically characterized novel tryptamines and its lead candidate CT-4201 (a psilocin prodrug for Major Depressive Disorder).

Ownership category

akta.pro rank

Product category

Psychedelic Drug Discovery

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Psychedelic drug discovery
• Tryptamine compound research
• Psilocin prodrug development
• Serotonergic therapeutics
• Pharmaceutical research services

Headquarters

HQ city

Issaquah

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Licensing: As a pre-revenue pharmaceutical drug discovery company, CaaMTech's primary revenue model centers on developing novel psychedelic-inspired therapeutics through clinical trials and out-licensing or partnering with larger pharmaceutical companies for commercialization. The company raised $22M Series A funding to support clinical trial advancements and pipeline expansion.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

CaaMTech is a pharmaceutical drug discovery company that designs, synthesizes, and crystallographically characterizes novel serotonergic (tryptamine-based) compounds, building a patent portfolio of next-generation psychedelic-inspired therapeutics. Its lead clinical asset, CT-4201 (a psilocin prodrug), is being advanced for Major Depressive Disorder, and the company out-licenses its compound library and drug candidates to pharmaceutical partners.

Product overview

CaaMTech is a pharmaceutical drug discovery company engineering novel small-molecule therapeutics focused on next-generation psychedelic-inspired medicines. The company's portfolio centers on CT-4201 (a psilocin prodrug for MDD) and its broader library of novel tryptamine compounds for treating mental health conditions. In 2025, CaaMTech spun out Transneural Therapeutics to develop TN-001 and other non-hallucinogenic neuroplastogens. The company maintains an extensive research platform encompassing psilocin prodrugs, DMT analogs, and proprietary compounds for clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• CT-4201 Psilocin Prodrug A novel psilocin prodrug with improved pharmacokinetics compared to psilocybin, being developed for the treatment of Major Depressive Disorder (MDD). The FDA has validated CaaMTech's functional unblinding strategy for clinical trials.
• Tryptamine Compound Library A proprietary library of novel tryptamine-based compounds synthesized and crystallographically characterized by CaaMTech for psychedelic drug research and development, including psilocin prodrugs and DMT analogs. Made available through research collaborations and licensing agreements with pharmaceutical and academic partners.
• 4-HO-DiPT Crystal Structure Solution First-ever crystal structure determination of 4-HO-DiPT, the active metabolite of the 4-glutarato-DiPT prodrug currently in Phase 2 clinical trials for postpartum depression and adjustment disorder.

Quantifiable outcome

• Functional unblinding solution validated by FDA for CT-4201 psilocin prodrug program
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• University of Massachusetts Dartmouth (Manke Lab)coreStrategic or Co-development PartnerCaaMTech has an ongoing research collaboration with UMass Dartmouth's Department of Chemistry and Biochemistry, led by Associate Professor Dr. David R. Manke. The collaboration has successfully synthesized over 70 novel tryptamines and structurally characterized over 40 compounds. The Manke Lab has become a global leader in novel tryptamine synthesis and characterization through this partnership.
• National Institutes of Health (NIDA DDRU)coreStrategic or Co-development PartnerCaaMTech entered into a Cooperative Research and Development Agreement (CRADA) with the Designer Drug Research Unit (DDRU) at NIDA Intramural Research Program to research synthetic tryptamine-based compounds. NIDA studies basic and preclinical pharmacology of novel designer tryptamine-based compounds for determining abuse liability and clinical utility.
• Leibniz Institute for Natural Product Research and Infection Biology (HKI Jena)coreStrategic or Co-development PartnerCaaMTech collaborates with the Hans Knöll Institute (HKI) in Jena, Germany, led by Prof. Dr. Dirk Hoffmeister, to research the chemical composition of psychedelic psilocybin-containing mushrooms. The research investigates terpene production and metabolic diversity in Psilocybe magic mushrooms.
• University of Washington (Center for Novel Therapeutics in Addiction Psychiatry)minorStrategic or Co-development PartnerDr. Nathan Sackett, Director of the University of Washington's Center for Novel Therapeutics in Addiction Psychiatry (NTAP), serves as a scientific advisor to CaaMTech. The center focuses on psychedelic medicines for treating substance use disorders and other neurological conditions.
• Alexander Shulgin Research Institute (ASRI)minorStrategic or Co-development PartnerCaaMTech collaborates with ASRI to conduct structural and chemical analyses of previously unreported compounds designed by the late Dr. Alexander Shulgin. Compounds from the 'Shulgin Vault' are being crystallized and analyzed using X-ray crystallography at the Manke Lab.
• Max Planck Institute for Chemical EcologyminorStrategic or Co-development PartnerCollaboration with researchers from the Max Planck Institute for Chemical Ecology on magic mushroom chemistry research, specifically investigating terpenoid production in Psilocybe cubensis mushrooms.
• Transneural TherapeuticsminorStrategic or Co-development PartnerCaaMTech spun out Transneural Therapeutics in April 2025 to develop novel non-hallucinogenic neuroplastogens. Transneural is developing TN-001, a dual 5-HT2A partial agonist/5-HT2B antagonist, under leadership of pharmaceutical veteran Charmaine Lykins.
• The Medical College of Wisconsin (McCorvy Lab)minorStrategic or Co-development PartnerCollaboration with researchers from The Medical College of Wisconsin on 5-MeO-DMT analog research investigating serotonin receptor modulation, specifically examining the influence of 5-HT1A on 5-HT2A-mediated psychedelic-like effects.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Compass Pathways: Public clinical-stage company developing psilocybin therapy (COMP360) for treatment-resistant depression. Directly comparable to CaaMTech in target indication (MDD), psychedelic mechanism, and pharmaceutical-grade drug development pathway; differentiated by much larger capital base and Phase 3-stage program.
• MindMed: Public neuropsychiatry company developing psychedelic-inspired medicines including psilocybin-based and LSD-based therapies for anxiety, depression, and ADHD. Comparable to CaaMTech as a psychedelic drug developer targeting CNS indications with novel serotonin-receptor-active compounds.
• Lykos Therapeutics (formerly MAPS PBC): Clinical-stage psychedelic therapeutics company developing MDMA-assisted therapy for PTSD. Directly comparable in navigating the FDA psychedelic regulatory pathway; its August 2024 NDA rejection is the very precedent shaping CaaMTech's functional unblinding strategy.
• GH Research: Clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Comparable tryptamine-based psychedelic approach and CNS target indication; CaaMTech's 5-MeO-DMT analog SAR research addresses overlapping chemistry space.
• Atai Life Sciences: Public clinical-stage biopharmaceutical company building a platform of psychedelic and non-psychedelic compounds for mental health. Highly comparable as a platform model backing multiple psychedelic programs, including a major investment in Compass Pathways.
• Beckley Psytech: Clinical-stage private company developing psychedelic-based medicines for neuropsychiatric conditions, including psilocybin for depression and a 5-MeO-DMT program. Comparable as a focused psychedelic CNS drug developer with synthetic chemistry capabilities.

Emerging players

• Delix Therapeutics: Clinical-stage neuroscience company developing novel neuroplastogens (non-hallucinogenic psychoplastogens) for depression and other CNS disorders. Closely comparable to CaaMTech's spun-out Transneural Therapeutics, working in the same non-hallucinogenic neuroplastogen space.
• Eleusis Therapeutics (formerly Eleusis Benefit Corporation): Clinical-stage private company exploring the therapeutic potential of psychedelics for inflammatory and psychiatric conditions. Comparable as a smaller psychedelic drug developer focused on serotonin receptor mechanisms, though with a different therapeutic focus area.

Broad incumbents

• Usona Institute: Non-profit medical research organization sponsoring psilocybin clinical trials for depression. Comparable to CaaMTech in advancing psilocybin-based MDD research; functions as a sponsor rather than a commercial developer and represents a different funding/structural model.

Others

• Alexander Shulgin Research Institute (ASRI): Non-profit research organization studying previously unreported compounds designed by Alexander Shulgin. Listed as a CaaMTech partner (Shulgin Vault collaboration); comparable as a contributor to the underlying chemistry/IP landscape rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/CaaMTechInc
• Facebookfacebook.com/CaaMTechInc
• LinkedInlinkedin.com/company/28425266

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CaaMTech